United Gene High-Tech Group Limited announced the board will inform based on a preliminary review of the unaudited consolidated management accounts of the Group for the six months ended December 31, 2013, the group is expected to record a substantial increase in the consolidated net loss for the six months ended December 31, 2013 as compared with the corresponding period in 2012, due to a loss on the acquisition of the convertible bonds issued by Extrawell Pharmaceutical Holdings Limited.
Innovative Pharmaceutical Biotech Limited
Equities
399
BMG4783W1073
Industrial Machinery & Equipment
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.205 HKD | 0.00% | +5.13% | -6.39% |
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-6.39% | 45.24M | |
+13.33% | 47.42B | |
-0.02% | 37.8B | |
+13.42% | 7.56B | |
+14.85% | 7.15B | |
-14.87% | 4.97B | |
+12.71% | 1.7B | |
+26.94% | 1.51B | |
-1.45% | 1.35B | |
+19.07% | 1.12B |
- Stock Market
- Equities
- 399 Stock
- News Innovative Pharmaceutical Biotech Limited
- United Gene High-Tech Group Limited Provides Earnings Guidance for the Six Months Ended December 31, 2013